Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06419985 · ClinicalTrials.gov registry record · Phase 2

Ketamine HCl Prolonged Release Oral Tablets for CRPS

A Phase 2 study, sponsored by University of Southern California.

Not yet
Registry status
Phase 2
Development phase
65
Enrollment target

NCT06419985: Clinical Trial Phase 2 study, sponsored by University of Southern California.

NCT06419985 is a Phase 2 study that has not yet begun recruiting, run by University of Southern California. The registered enrollment target is 65 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06419985, a Phase 2 study, has not yet begun recruiting, sponsored by University of Southern California.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
65 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the efficacy of Ketamine HCl Prolonged Release (PR) tablets in participants with pain due to complex regional pain syndrome (CRPS). Additionally, this trial will explore the feasibility of the trial design through dosing compliance, clinical instruments for safety and quality of life measurements, and pharmacokinetic profile.

Interventions

  • DRUG 80mg/day Ketamine HCl Prolonged Release
  • DRUG 160mg/day Ketamine HCl Prolonged Release

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2026-07
Est. Completion 2028-07
Phase Phase 2
University of Southern California

617 total trials

What is known before NCT06419985 opens enrollment

NCT06419985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower).

The record links to 0 conditions, and to 2 interventions - of which 80mg/day Ketamine HCl Prolonged Release is the first listed.

NCT06419985 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06419985 about?

NCT06419985 is a clinical study titled "Ketamine HCl Prolonged Release Oral Tablets for CRPS". The purpose of this study is to evaluate the efficacy of Ketamine HCl Prolonged Release (PR) tablets in participants with pain due to complex regional pain syndrome (CRPS). Additionally, this trial will explore the feasibility of the trial design through dosing compliance, clinical instruments for ...

What is the current status of trial NCT06419985?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2026-07. Estimated completion is 2028-07.

What interventions are being tested in trial NCT06419985?

The interventions under investigation include: 80mg/day Ketamine HCl Prolonged Release (DRUG), 160mg/day Ketamine HCl Prolonged Release (DRUG).

Who is sponsoring clinical trial NCT06419985?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06419985's enrollment target sits among peer trials

65 987th of 2000 higher than 1,005 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT06419985, the US trial registry maintained by the National Library of Medicine. NCT06419985 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.